A Phase 1b Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Trial Profile

A Phase 1b Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Demcizumab (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2016 Updated results from this trial were presented at the 2016 ASCO GI Symposium, according to an OncoMed Pharmaceuticals media release.
    • 22 Jan 2016 Updated results from this trial published in an OncoMed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top